News archive
July 2026
-
Media Release
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks,… -
Story Medicines Immunology
The Future of Autoimmune Disease: A Q&A You Need to Read
1 in 5 Americans lives with an autoimmune disease, yet many have no or very limited treatment options. Christy Siegel, SVP and TA Head, Immunology, Novartis US, shares how we aim to change that.
-
Story Medicines
Meet Colin: A Novartis Scientist Looking for New Breakthroughs
Colin works on a cryo-electron microscope the size of a room using a process that earned a team of scientists a Nobel Prize. Learn how his work is advancing the ways we treat disease.
June 2026
-
Story Education and Awareness
Carrie Ann Inaba: “I Wouldn’t Be Who I Am Without Sjögren's Disease"
For World Sjögren's Day, dancer and TV personality Carrie Ann Inaba shares her story of diagnosis, living with the disease, and self-advocacy
-
Media Release
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety… -
Media Release
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous resultsDel-brax indicates potential to become… -
Media Release
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted … -
Media Release
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1 Vanrafia reduced protein in urine by 38.3%… -
Media Release
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent with established Cosentyx profile1,2… -
Story Education and Awareness
New Survey Reveals 4 Things Patients with HS Really Need
The hidradenitis suppurativa (HS) Community Mapping Project surveyed patients to create a roadmap for change. Here's what they shared.
-
Story Medicines
Carter’s Story: My Mom's Journey with Cancer Inspired Me. Now I Help Make Medicines for Patients
For Carter Jaynes, helping to produce doses of RLT is deeply personal. See how a move to our new RLT facility in Carlsbad can help him reach even more patients.
-
Media Release
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1 Clinically relevant 15.2%…